Naltrexone Treatment Centers in Hawaii

Yes. MAT with methadone or buprenorphine is the recommended standard of care in pregnancy — ACOG and SAMHSA both endorse it. Hawaii providers coordinate with obstetrics to monitor mother and baby throughout pregnancy and the neonatal period.

Most Hawaii programs include routine urine drug screens in the program fee. Baseline lab work (liver function, pregnancy test, ECG for methadone) may be billed separately — $30–$150 depending on insurance status. Ask about lab fees at intake.

Yes — Med-QUEST can pay retroactively for up to 3 months of prior treatment in most cases, provided you were eligible during that period. Save all receipts and itemized statements from naltrexone providers and submit them to the Medicaid enrollment caseworker.

Yes. COBRA continues your former employer’s health plan unchanged for up to 18 months, including MAT benefits. The monthly COBRA premium is higher than a marketplace plan for most people; explore Marketplace options too before the 60-day COBRA deadline.

For methadone, SAMHSA’s 2024 final rule allows OTPs in Hawaii to grant up to 28 days of take-home doses once clinical-stability criteria are met. For buprenorphine, 30-day prescriptions are standard and 90-day fills are permitted in many Hawaii plans. Long-acting naltrexone is a single monthly injection, so no take-home supply applies.

Common reasons include lifestyle stabilization (patient and clinician agree to taper), cost barriers, side effects, travel or employment disruption, and desire to try naltrexone after tapering. Many patients resume treatment later — clinics welcome return visits without judgment.

Yes. Transferring to a different Hawaii provider is routine; the new clinic will request records with your consent and continue your current dose. There is no penalty for switching providers — clinical compatibility matters.

Usually yes. Hawaii programs following low-barrier protocols provide the first buprenorphine dose or naltrexone prescription on day one. Methadone first doses are administered in-clinic and require SAMHSA-certified protocols that are typically completed during the intake visit.

Long-term opioid-agonist therapy (methadone, buprenorphine) can lower testosterone in some men and affect menstruation in some women. Annual hormone panels are reasonable. Switching medications or adjusting dose resolves most cases; endocrinology referral is available in Hawaii for persistent issues.

Yes. Methadone and buprenorphine are the evidence-based standard of care in pregnancy, endorsed by ACOG and SAMHSA. Staying on MAT protects both mother and fetus; unmedicated withdrawal is riskier than continued MAT. Hawaii providers coordinate care with obstetrics.

Federal rules require all SAMHSA-certified OTPs to offer counseling alongside methadone. Buprenorphine and naltrexone prescribing does not mandate counseling, but Hawaii providers strongly recommend it. Most insurance plans and Med-QUEST cover integrated counseling as part of the MAT benefit.

No — medical records must use your legal name for billing, insurance, and DEA compliance. However, 42 CFR Part 2 confidentiality means that legal name is protected from disclosure. Pseudonymous treatment is not available in MAT.